Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESKA: Anakinra in Non-COVID-19 Related ARDS
2021-006644-27Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria di Udine
- Start
- Aug 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of anakinra in acute respiratory distress syndrome (ARDS), sponsored by Azienda Ospedaliero-Universitaria di Udine. Primary endpoint: Composite outcome of 28-day mortality and ventilation-free days. Started Aug 2022; status: active.
02
Drugs
anakinra
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2021-006644-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006644-27.